文献速递胃肠动力与功能性疾病

随机临床试验:经结肠镜粪菌移植对比自体安慰剂治疗肠易激综合征

Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-28

FMT组在12周时症状评分较基线有一过性下降(P=0.01),且微生物组成向供体转变、粪便含水量显著降低,但单次结肠镜粪菌移植不能推荐作为IBS的临床治疗。

要点

  • 单次经结肠镜粪菌移植未使IBS患者达到持续症状缓解的主要终点。
  • FMT组12周时症状评分较基线一过性下降,但组间临床应答人数无差异。
  • FMT后患者微生物组成向供体转变且粪便含水量显著降低。

核心结论

  • 单次经结肠镜粪菌移植仅提供一过性症状缓解,不能推荐作为IBS的临床治疗。

研究设计与样本

  • 主要终点为IBS症状严重程度评分持续至少降低50分。
  • 次要终点包括焦虑抑郁水平、生活质量、肠道菌群和粪便含水量。

主要发现

  • 两组均未达到主要终点。
  • FMT组治疗12周时平均IBS症状严重程度评分较基线有一过性下降(P=0.01)。
  • 两组12周时达到临床应答的患者数无差异。
  • FMT组患者微生物组成向供体转变,粪便含水量较基线显著降低。
  • FMT后IBS症状减轻的患者抑郁评分下降,而安慰剂组症状减轻者未出现该变化。

临床怎么用

  • 临床实践中不推荐单次经结肠镜粪菌移植用于治疗IBS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Irritable bowel syndrome (IBS) has been associated with microbial dysbiosis. AIM: To investigate the efficacy of faecal microbiota transplantation (FMT) in the treatment of IBS. METHODS: Forty-nine IBS patients were randomised to receive autologous or allogenic FMT via colonoscopy. The primary endpoint was a sustained, minimum of 50-point, reduction in the IBS Symptom Severity Score. The secondary outcomes were levels of anxiety and depression, changes in quality of life, gut microbiota and faecal water content as assessed with validated questionnaires, intestinal microbiota composition and stool dry weight. RESULTS: The primary endpoint was not achieved in either group. However, there was a transient reduction in the mean IBS Symptom Severity Score in the FMT group at 12 weeks after treatment as compared to baseline (P = 0.01). The groups did not differ in the number of patients achieving clinical response at 12 weeks. In the FMT-treated patients, microbial composition had changed to resemble that of the donor and the stool water content decreased significantly compared to baseline. The depression score decreased in patients with a reduction in IBS symptoms after FMT, but not in those placebo-treated patients who experienced a reduction in IBS symptoms. CONCLUSIONS: FMT provided only a transient relief of symptoms, although it induced a sustained alteration in the microbiota of IBS patients. Therefore, FMT delivered by a single infusion via colonoscopy cannot be recommended as a treatment for IBS in clinical practice. ClinicalTrials.Org, Trial registration number: NCT03561519.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lahtinen P, Jalanka J, Hartikainen A, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther. 2020. PMID: 32343000. doi:10.1111/apt.15740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。